TW200413000A - Intrinsic repair factor producing accelerator - Google Patents

Intrinsic repair factor producing accelerator Download PDF

Info

Publication number
TW200413000A
TW200413000A TW092128052A TW92128052A TW200413000A TW 200413000 A TW200413000 A TW 200413000A TW 092128052 A TW092128052 A TW 092128052A TW 92128052 A TW92128052 A TW 92128052A TW 200413000 A TW200413000 A TW 200413000A
Authority
TW
Taiwan
Prior art keywords
alkyl
group
agonist
agonists
compound
Prior art date
Application number
TW092128052A
Other languages
English (en)
Chinese (zh)
Inventor
Yoshiki Sakai
Akio Nishiura
Teppei Ogata
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of TW200413000A publication Critical patent/TW200413000A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
TW092128052A 2002-10-10 2003-10-09 Intrinsic repair factor producing accelerator TW200413000A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002298079 2002-10-10
JP2002318830 2002-10-31
JP2003117604 2003-04-22

Publications (1)

Publication Number Publication Date
TW200413000A true TW200413000A (en) 2004-08-01

Family

ID=32096713

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092128052A TW200413000A (en) 2002-10-10 2003-10-09 Intrinsic repair factor producing accelerator

Country Status (10)

Country Link
US (3) US7547715B2 (enExample)
EP (2) EP1563846B1 (enExample)
JP (2) JP4497320B2 (enExample)
AU (1) AU2003272963A1 (enExample)
DK (2) DK2465537T3 (enExample)
ES (2) ES2584606T3 (enExample)
HU (1) HUE029417T2 (enExample)
PT (2) PT2465537T (enExample)
TW (1) TW200413000A (enExample)
WO (1) WO2004032965A1 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004032965A1 (ja) 2002-10-10 2004-04-22 Ono Pharmaceutical Co., Ltd. 内因性修復因子産生促進剤
WO2005072743A1 (ja) * 2004-01-30 2005-08-11 Ono Pharmaceutical Co., Ltd. 気管支拡張剤
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
JP4775663B2 (ja) * 2005-03-30 2011-09-21 地方独立行政法人 大阪府立病院機構 血管新生制御方法
US9422521B2 (en) * 2005-09-12 2016-08-23 Es Cell International Pte Ltd. Differentiation of pluripotent stem cells with a kinase inhibitor or PGI2
WO2007061889A2 (en) 2005-11-17 2007-05-31 Biomimetic Therapeutics, Inc. Maxillofacial bone augmentation using rhpdgf-bb and a biocompatible matrix
ES2427993T3 (es) 2006-02-09 2013-11-05 Biomimetic Therapeutics, Llc Composiciones y métodos para el tratamiento de hueso
CN101495623B (zh) 2006-03-24 2013-09-11 儿童医疗中心有限公司 调节造血干细胞生长的方法
US9161967B2 (en) 2006-06-30 2015-10-20 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column
WO2008005427A2 (en) 2006-06-30 2008-01-10 Biomimetic Therapeutics, Inc. Pdgf-biomatrix compositions and methods for treating rotator cuff injuries
US20080171972A1 (en) * 2006-10-06 2008-07-17 Stopek Joshua B Medical device package
ES2459743T3 (es) * 2006-10-19 2014-05-12 Ono Pharmaceutical Co., Ltd. Preparación de liberación sostenida para terapia de regeneración tisular
EP2679221B1 (en) 2006-10-20 2020-09-23 Children's Medical Center Corporation Method to enhance tissue regeneration
AU2013213727B2 (en) * 2006-10-20 2016-03-17 Children's Medical Center Corporation Method to enhance tissue regeneration
EP2085088A4 (en) * 2006-10-26 2012-08-29 Ono Pharmaceutical Co ADHESIVE PREPARATION
EP2462895B1 (en) 2006-11-03 2016-11-02 BioMimetic Therapeutics, LLC Compositions and methods for arthrodetic procedures
WO2008058766A1 (en) * 2006-11-16 2008-05-22 Bayer Schering Pharma Aktiengesellschaft Ep2 and ep4 agonists as agents for the treatment of influenza a viral infection
JP2008195660A (ja) * 2007-02-14 2008-08-28 Kitasato Institute 中枢循環改善薬
CA2715254A1 (en) 2008-02-07 2009-08-13 Biomimetic Therapeutics, Inc. Compositions and methods for distraction osteogenesis
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
ES2557303T3 (es) * 2008-06-23 2016-01-25 Nippon Shinyaku Co., Ltd. Agente terapéutico para la estenosis del canal espinal
CN102231992B (zh) 2008-09-09 2015-05-20 生物模拟治疗公司 用于治疗肌腱和韧带损伤的血小板衍生生长因子的组合物和方法
US9056085B2 (en) 2009-02-03 2015-06-16 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
US9051548B2 (en) 2009-02-03 2015-06-09 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
US20100267826A1 (en) * 2009-04-20 2010-10-21 The Board Of Trustees Of The Leland Stanford Junior University Treatment of ischemic episodes and cerebroprotection through Prostaglandin E2 (PGE2) EP2 and/or EP4 receptor agonists
US20100305203A1 (en) * 2009-05-27 2010-12-02 Sucampo Ag Method for modulating claudin mediated functions
US8569279B2 (en) 2009-05-27 2013-10-29 Sucampo Ag Method for modulating claudin mediated functions
EP3167875A1 (en) * 2009-05-27 2017-05-17 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate meloxicam compositions
US9387206B2 (en) 2009-11-03 2016-07-12 Pharnext Therapeutic approaches for treating Alzheimer's disease
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
BR112012020566B1 (pt) 2010-02-22 2021-09-21 Biomimetic Therapeutics, Llc Composição de fator de crescimento derivado de plaqueta
MX2013001227A (es) * 2010-07-30 2013-04-24 Allergan Inc Compuestos y metodos para reparacion de piel.
US20120142684A1 (en) * 2010-12-02 2012-06-07 Allergan, Inc. Compounds and methods for skin repair
BR112013021035A2 (pt) * 2011-02-17 2016-10-11 Allergan Inc composições e métodos de reposição de tecido macio aperfeiçoados
EP2678022A2 (en) * 2011-02-23 2014-01-01 Allergan, Inc. Compositions and improved soft tissue replacement methods
ES2665569T3 (es) 2011-03-01 2018-04-26 Pharnext Tratamiento de la isquemia cerebral
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
US10010515B2 (en) 2011-03-01 2018-07-03 Pharnext Therapeutic approaches for treating Parkinson's disease
US9241933B2 (en) 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
WO2013082243A1 (en) 2011-12-02 2013-06-06 Fate Therapeutics, Inc. Enhanced stem cell composition
JP6106688B2 (ja) 2011-12-02 2017-04-05 フェイト セラピューティクス，インコーポレイテッド 虚血を処置する改善された方法
WO2014046065A1 (ja) 2012-09-21 2014-03-27 国立大学法人大阪大学 心筋・血管再生デバイスとしての重症心不全治療材
JP6400479B2 (ja) * 2012-10-29 2018-10-03 株式会社カルディオ 肺疾患特異的治療剤
CA2890034A1 (en) * 2012-11-16 2014-05-22 Allergan, Inc. Skin wound healing and scar reduction with prostaglandin ep4 agonist combinations
US10851412B2 (en) 2013-03-15 2020-12-01 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
JP6449166B2 (ja) * 2013-10-15 2019-01-09 小野薬品工業株式会社 薬剤溶出性ステントグラフト
US9763911B2 (en) * 2013-12-12 2017-09-19 Mayo Foundation For Medical Education And Research Prostacyclin compositions for regulation of fracture repair and bone formation
US9918994B2 (en) 2016-03-04 2018-03-20 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for muscle regeneration using prostaglandin E2
JPWO2018124236A1 (ja) 2016-12-27 2019-11-14 国立大学法人大阪大学 難治性心疾患治療用医薬組成物
WO2018227134A1 (en) 2017-06-09 2018-12-13 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for preventing or treating muscle conditions
WO2019023579A1 (en) * 2017-07-27 2019-01-31 The Mclean Hospital Corporation METHODS AND COMPOSITIONS RELATING TO THE TREATMENT OF PATHOLOGIES MEDIATED BY NURR1 AND PPARY
US20210113464A1 (en) * 2017-11-27 2021-04-22 Osaka University Disease-site-specific liposomal formulation
JP7233087B2 (ja) * 2019-03-18 2023-03-06 公立大学法人横浜市立大学 抗動脈硬化剤
CA3155464A1 (en) 2019-10-28 2021-05-06 Mark Williams Use of glutamate 2b receptor antagonists and sigma receptor agonsists as antitussives
CA3167058A1 (en) 2020-02-12 2021-08-19 Cytoagents, Inc. Compositions and methods for treating coronavirus infections
EP4126054A4 (en) * 2020-03-31 2024-05-15 Ensysce Biosciences, Inc. METHOD OF TREATING VIRUS INFECTIONS WITH NAFAMOSTAT
KR20220040169A (ko) * 2020-09-23 2022-03-30 (주)아이엠디팜 나파모스타트 또는 이의 약제학적으로 허용가능한 염을 포함하는 경구투여용 제제
GB202211232D0 (en) 2022-08-02 2022-09-14 Heptares Therapeutics Ltd Prostaglandin EP4 receptor agonist compounds

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE555319A (enExample) 1956-03-21 1900-01-01
US3095355A (en) 1961-10-12 1963-06-25 Revlon Aerosol composition
JPS503362B1 (enExample) 1970-06-10 1975-02-04
JPS5231404B1 (enExample) 1971-04-28 1977-08-15
US3965143A (en) 1974-03-26 1976-06-22 G. D. Searle & Co. 16-Oxygenated prostanoic acid derivatives
US4132738A (en) 1978-02-23 1979-01-02 Miles Laboratories, Inc. Preparation of 15-deoxy-16-hydroxyprostaglandins
DE2912409A1 (de) 1978-03-31 1979-10-11 Ono Pharmaceutical Co 6,9-methano-pgi tief 2 -analoge
JPS54130543A (en) 1978-03-31 1979-10-09 Ono Pharmaceut Co Ltd Prostagladin i2 analog, and its preparation
JPS57156460A (en) 1981-03-20 1982-09-27 Ono Pharmaceut Co Ltd Stabilized composition of prostaglandin and prostaglandin mimic compound, and its preparation
US4650804A (en) 1984-03-30 1987-03-17 Fujisawa Pharmaceutical Co., Ltd. Quinolizinone compounds and pharmaceutical composition comprising the same, useful as anti-ulcerative and anti-allergic agents
JPS6130519A (ja) 1984-07-23 1986-02-12 Dainippon Pharmaceut Co Ltd 脳神経細胞の酸素欠乏性疾患治療剤
JPS62134787A (ja) 1985-12-06 1987-06-17 株式会社クボタ 自動販売機の商品払出し装置
KR100191137B1 (ko) * 1992-07-21 1999-06-15 사노 가즈오 옥심 유도체
US5462968A (en) 1994-01-19 1995-10-31 Allergan, Inc. EP2 -receptor agonists as agents for lowering intraocular pressure
US5698598A (en) 1995-08-04 1997-12-16 Allergan EP2 -receptor agonists as agents for lowering intraocular pressure
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
NO317155B1 (no) * 1997-02-04 2004-08-30 Ono Pharmaceutical Co <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater
JP3162668B2 (ja) 1997-02-04 2001-05-08 小野薬品工業株式会社 ω−シクロアルキル−プロスタグランジンＥ２誘導体
PT1008588E (pt) 1997-02-10 2003-09-30 Ono Pharmaceutical Co Derivados da 11,15-o-diaklquil-prostaglandina e processo de producao dos mesmos e farmaco que os contem como ingrediente activo
WO1998058911A2 (en) 1997-06-23 1998-12-30 Pfizer Inc. Prostaglandin agonists
SE9702681D0 (sv) 1997-07-10 1997-07-10 Pharmacia & Upjohn Ab Method and composition for treatment of impotence
EP1008349A4 (en) 1997-08-27 2004-01-14 Mitsubishi Pharma Corp PROMOTORS OF NEOVASCULARIZATION
US6124314A (en) 1997-10-10 2000-09-26 Pfizer Inc. Osteoporosis compounds
UA67754C2 (uk) 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
US5877211A (en) 1997-11-21 1999-03-02 Allergan EP2 receptor agonists as neuroprotective agents for the eye
WO1999033794A1 (en) 1997-12-25 1999-07-08 Ono Pharmaceutical Co., Ltd. φ-CYCLOALKYL-PROSTAGLANDIN E2 DERIVATIVES
WO1999043736A1 (en) 1998-02-27 1999-09-02 Ono Pharmaceutical Co., Ltd. Carrier polymers migrating into target organs and drug-containing polymers
JP4123568B2 (ja) 1998-05-06 2008-07-23 小野薬品工業株式会社 ６−オキソ−ｐｇｅ１化合物、それらの製造方法およびそれらを有効成分として含有するプロスタグランジンｅ２受容体作働薬
TWI249520B (en) * 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
US6235780B1 (en) 1998-07-21 2001-05-22 Ono Pharmaceutical Co., Ltd. ω-cycloalkyl-prostaglandin E1 derivatives
JP2000086517A (ja) * 1998-09-16 2000-03-28 Ono Pharmaceut Co Ltd アロディニア治療剤
AUPP608898A0 (en) 1998-09-23 1998-10-15 Fujisawa Pharmaceutical Co., Ltd. New use of prostaglandin E2 antagonists
US6437146B1 (en) 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
JP2002527400A (ja) 1998-10-15 2002-08-27 メルク エンド カムパニー インコーポレーテッド 骨形成刺激方法
JP2000239188A (ja) 1998-12-22 2000-09-05 Mitsubishi Chemicals Corp 育毛剤
WO2000038663A2 (en) 1998-12-24 2000-07-06 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
AU2183800A (en) 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Prostaglandin e agonists for treatment of dry eye
WO2000038667A2 (en) 1998-12-24 2000-07-06 Alcon Laboratories, Inc. Prostaglandin e agonists for treatment of glaucoma
SE9900025D0 (sv) 1999-01-08 1999-01-08 Synphora Ab Method and composition for treatment of female sexual dysfunction
CA2332375A1 (en) 1999-03-16 2000-09-21 Masafumi Isogaya Cervical ripening agent and cervical ripening method
EP1080728A1 (en) 1999-03-16 2001-03-07 Toray Industries, Inc. Prostaglandin ep4 receptor agonist and treatment method
ES2274378T3 (es) 1999-08-10 2007-05-16 Glaxo Group Limited Ligando del receptor ep4 y uso contra dolor neuropatico, cancer de colon,hiv y migraña.
AUPQ253199A0 (en) 1999-08-30 1999-09-23 Fujisawa Pharmaceutical Co., Ltd. Non-prostanoid prostaglandin I2-agonist
WO2001046140A1 (en) 1999-12-22 2001-06-28 Pfizer Products Inc. Ep4 receptor selective agonists in the treatment of osteoporosis
IL141120A0 (en) 2000-01-31 2002-02-10 Pfizer Prod Inc Use of prostaglandin (pge2) receptor 4 (epa) selective agonists for the treatment of acute and chronic renal failure
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
WO2001072268A1 (en) * 2000-03-31 2001-10-04 Toray Industries, Inc. Hair growth or hair formation controlling agents
FR2812190B1 (fr) 2000-07-28 2003-01-31 Oreal Utilisation d'agonistes non prostanoiques des recepteurs des prostaglandines ep-2 et/ou ep-4 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils
US6376533B1 (en) 2000-10-20 2002-04-23 Allergan Sales, Inc. Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists
US20020161026A1 (en) 2000-11-07 2002-10-31 Paralkar Vishwas M. Combination therapies for the stimulation of bone growth
SI1339678T1 (sl) 2000-11-27 2007-12-31 Pfizer Prod Inc Selektivni agonisti EP4 receptorja pri zdravljenju osteoporoze
GB0030541D0 (en) 2000-12-14 2001-01-31 Glaxo Group Ltd Medical uses
GB0103269D0 (en) 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
US7410991B2 (en) 2001-10-23 2008-08-12 Laboratoires Serono S.A. Pyrazolidinone compounds as ligands of the prostaglandin EP2 and/or EP4 receptors
US7335680B2 (en) 2001-12-20 2008-02-26 Laboratoires Serono Sa Pyrrolidine derivatives as prostaglandin modulators
WO2004032965A1 (ja) * 2002-10-10 2004-04-22 Ono Pharmaceutical Co., Ltd. 内因性修復因子産生促進剤
ES2459743T3 (es) 2006-10-19 2014-05-12 Ono Pharmaceutical Co., Ltd. Preparación de liberación sostenida para terapia de regeneración tisular

Also Published As

Publication number Publication date
ES2393321T3 (es) 2012-12-20
EP1563846A4 (en) 2009-11-04
PT1563846E (pt) 2012-11-13
US20080299089A1 (en) 2008-12-04
US7547715B2 (en) 2009-06-16
ES2584606T3 (es) 2016-09-28
US8436026B2 (en) 2013-05-07
JP5287761B2 (ja) 2013-09-11
PT2465537T (pt) 2016-08-03
HUE029417T2 (en) 2017-02-28
EP1563846A1 (en) 2005-08-17
US20130225643A1 (en) 2013-08-29
EP2465537B1 (en) 2016-06-29
DK2465537T3 (en) 2016-09-19
US8642630B2 (en) 2014-02-04
JP2010120964A (ja) 2010-06-03
US20060069018A1 (en) 2006-03-30
JPWO2004032965A1 (ja) 2006-02-09
AU2003272963A1 (en) 2004-05-04
EP2465537A1 (en) 2012-06-20
EP1563846B1 (en) 2012-08-29
WO2004032965A1 (ja) 2004-04-22
JP4497320B2 (ja) 2010-07-07
DK1563846T3 (da) 2012-12-17

Similar Documents

Publication Publication Date Title
TW200413000A (en) Intrinsic repair factor producing accelerator
US7785632B2 (en) Thyroid hormone analogs and methods of use
ES2535005T3 (es) Formulaciones de nanopartículas y de polímeros para análogos, antagonistas y formulaciones de la hormona tiroidea, y usos de los mismos
ES2459743T3 (es) Preparación de liberación sostenida para terapia de regeneración tisular
EA038598B1 (ru) Способы репарации и регенерации тканей
KR20080103637A (ko) 지방유래 줄기세포를 함유하는 사지말단부 허혈성 질환의세포치료용 조성물
TWI798320B (zh) 神經系統疾患治療劑
CN112451486A (zh) 用顺铂脂质复合物预防癌症的肺部复发
JP2021512921A (ja) 癌療法に対するイブジラストおよび第二の薬剤を使用した方法ならびに投与レジメン
JP6916933B2 (ja) 血小板増加性癌患者における転移性疾患の予防及び治療
JPWO2016068228A1 (ja) 薬剤徐放担体及び薬剤徐放方法
CN101198334A (zh) 前列腺素化合物和质子泵抑制剂用于治疗肠胃病的联合应用
CN105163732B (zh) 用于治疗眼科疾病和病症的方法
CN116942652A (zh) 基质金属蛋白酶抑制剂在制备预防或治疗骨关节炎软骨损伤药物中的应用
TWI395592B (zh) 由聚乳酸－甘醇酸（ｐｏｌｙ（ｌａｃｔｉｃ－ｃｏ－ｇｌｙｃｏｌｉｃ ａｃｉｄ））微小球控制釋放副甲狀腺素之方法
CN109985047B (zh) 5α-雄甾-3β,5,6β-三醇在制备治疗出血性脑卒中药物中的应用
TWI602563B (zh) 橙黃醯胺雙肽衍生物用於治療或預防血管新生相關疾病
JP5424291B2 (ja) 骨髄細胞の動員剤および動員方法
CA2805552C (en) Polymeric conjugates of anti-angiogenesis agents
CN119745887A (zh) 小分子激动剂tepp-46在制备预防和/或治疗主动脉瘤及相关心血管疾病的药物中的应用
JP2015003902A (ja) 血管新生阻害剤